雾化吸入重组人干扰素α1b在重症EV71手足口病中的疗效观察

Clinical observation on children with severe hand, foot and mouth disease caused by EV71 treated with nebulized human recombinant interferon α1b

目的探讨雾化吸入重组人干扰素α1b(IFN-α1b)治疗重症肠道病毒71型(EV71)手足口病的临床疗效及安全性。方法 42例重症EV71手足口病患儿,随机分成治疗组和对照组,各21例。对照组给予静脉丙种球蛋白(IVIG)和甘露醇等常规治疗,治疗组在对照组基础上加用IFN-α1b雾化吸入治疗,比较两组的治疗效果。结果治疗组惊跳、眼球运动异常的持续时间与对照组比较,差异无统计学意义(P>0.05);治疗组持续高热、精神萎靡、四肢震颤、肢体无力的持续时间分别为(2.0±0.5)、(3.2±0.4)、(2.6±1.1)、(4.9±2.1)d,均短于对照组的(3.2±1.5)、(5.5±1.7)、(4.2±2.1)、(7.8±3.6)d,差异有统计学意义(P<0.05)。结论雾化吸入IFN-α1b能加速重症EV71手足口病患儿的神经系统表现和其他临床表现的改善,且安全可靠。

Objective To investigate effect and safety of nebulized human recombinant interferon α1b（IFN-α1b） in children with severe hand, foot and mouth disease caused by enterovirus type 71（EV71）. MethodsA total of 42 children with severe hand, foot and mouth disease were randomly divided into treatment group and control group, with 21 cases in each group. The control group had conventional treatment as immunoglobulin（IVIG） and mannitol, and control group also received nebulized IFN-α1b. Therapeutic effect was compared in two groups. Results The treatment group had no statistical significant differences in duration of startle reflex and abnormal eye movements compared with control group（P〉0.05）. The treatment group had continuous fever, mental fatigue, abnormal eye movements and limb weakness as（2.0±0.5）、（3.2±0.4）、（2.6±1.1）、（4.9±2.1） d, which were shorter than（3.2±1.5）、（5.5±1.7）、（4.2±2.1）、（7.8±3.6） d in control group, and differences had statistical significance（P〈0.05）. Conclusion Nebulized IFN-α1b can quicken neurological and other clinical manifestations of children with severe hand, foot and mouth disease caused by EV71 with safety and security.